The GLP-1 Museum

The GLP-1 Museum is a free online museum of GLP-1 medicines: where they came from, who found them, and how a gut hormone became some of the most talked-about drugs in the world. It is made by GLP-1 Studio, the team behind GLP-1 Nation.

GLP-1 Nation covers the news as it happens. The museum covers everything that happened before, so the headlines make sense.

A short history of GLP-1 medicines

  1. 1980s: The hormone is found. Scientists studying the glucagon gene find a second hormone made in the gut, glucagon-like peptide-1. Svetlana Mojsov, Joel Habener and Jens Juul Holst are among the researchers who show it helps the body release insulin after a meal.
  2. 1990s: A hormone that disappears in minutes. Natural GLP-1 is broken down by the body within a couple of minutes, far too fast to work as a medicine. The search begins for a version that lasts.
  3. 1992: The Gila monster. John Eng, a researcher at the Bronx VA, reports exendin-4, a compound in Gila monster venom that acts like GLP-1 but lasts much longer.
  4. 2005: The first GLP-1 medicine. The FDA approves exenatide (Byetta), based on exendin-4, for type 2 diabetes.
  5. 2010: Once a day. Liraglutide (Victoza) is approved for type 2 diabetes. In 2014 the same medicine is approved for weight management as Saxenda.
  6. 2017: Ozempic. Semaglutide is approved as Ozempic, a once-weekly shot for type 2 diabetes. A daily pill version, Rybelsus, follows in 2019.
  7. 2021: Wegovy. Semaglutide is approved for chronic weight management as Wegovy, and GLP-1 medicines move from diabetes clinics into everyday conversation.
  8. 2022: Mounjaro. Tirzepatide, which acts on both GLP-1 and GIP receptors, is approved as Mounjaro for type 2 diabetes. In 2023 it is approved for weight management as Zepbound.
  9. 2024: The Lasker Award. Joel Habener, Svetlana Mojsov and Lotte Bjerre Knudsen receive the Lasker Award for the discovery and development of GLP-1 medicines.

Inside the museum

Visit the GLP-1 Museum